Rheumatoid arthritis

Cell

Volumn 85, Issue 3, 1996, Pages 307-310

  Feldmann, Marc ^a   Brennan, Fionula M ^a   Maini, Ravinder N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; B LYMPHOCYTE; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 0030003058     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81109-5     Document Type: Review

References (35)

1. Arend, W.P., and Dayer, J.-M. (1995). Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38, 151-60.
2. Brennan, F.M., Chantry, D., Jackson, A., Maini, R., and Feldmann, M. (1989). Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247.
3. Courtenay, J.S., Dallman, M.J., Dayan, A.D., Martin, A., and Mosedale, B. (1980). Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283, 666-668.
4. Cush, J.J., and Lipsky, P.E. (1988). Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum. 31, 1230-1238.
5. Di Giovine, F.S., Nuki, G., and Duff, G.W. (1988). Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. 47, 768-772.
6. Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H., and Woody, J.N. (1994). Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110.
7. Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F.M., Walker, J., Bijl, H., Ghrayeb, J., and Woody, J. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum. 36, 1681-1690.
8. Fava, R., Olsen, N., Keski-Oja, J., Moses, H., and Pincus, T. (1989). Active and latent forms of transforming growth factor β activity in synovial effusions. J. Exp. Med. 169, 291-296.
9. Feldmann, M., Brennan, F.M., and Maini, R.N. (1996). Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440.
10. Firestein, G.S., and Zvaifler, N.J. (1990). How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33, 768-773.
11. Fong, Y., Tracey, K.J., Moldawer, L.L., Hesse, D.G., Manogue, K.B., Kenney, J.S., Lee, A.T., Kuo, G.C., Allison, A.C., Lowry, S.F., and Cerami, A. (1989). Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170, 1627-1633.
12. Gregersen, P.K., Silver, J., and Winchester, R.J. (1987). The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213.
13. Hammer, J., Gallazzi, F., Bono, E., Karr, R.W.,Guenot, J., Valsasnini, P., Nagy, Z.A., and Sinigaglia, F. (1995). Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association. J. Exp. Med. 181, 1847-1855.
14. Janossy, G., Panayai, G., Duke, O., Bofill, M., Poulter, L.W., and Goldstein, G. (1981). Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. The Lancet 839-841.
15. Katsikis, P., Chu, C.Q., Brennan, F.M., Maini, R.N., and Feldmann, M. (1994). Immunoregulatory role of interleukin-10 (IL-10) in rheumatoid arthritis. J. Exp. Med. 179, 1517-1527.
16. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G. (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031.
17. Kirkham, B.W., Thien, F., Pelton, B.K., Pitzalis, C., Amlot, P., Denman, A.M., and Panayi, G.S. (1992). Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J. Rheumatol. 19, 1348-1352.
18. Maini, R.N., Elliott, M.J., Brennan, F.M., Williams, R.O., Chu, C.Q., Paleolog, E., Charles, P.J., Taylor, P.C., and Feldmann, M. (1995). Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144, 195-223.
19. Moreland, L.W., Sewell, K.L., Trentham, D.E., Bucy, R.P., Sullivan, W.F., Schrohenloher, R.E., Shmerling, R.H., Parker, K.C., Swartz, W.G., Woodworth, T.G., and Koopman, W.J. (1995). Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis: a double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum. 38, 1177-1186.
20. Mosmann, T.R., and Coffman, R.L. (1989). Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173.
21. Olee, T., Lu, E.W., Huang, D.F., Soto-Gil, R.W., Deftos, M., Kozin, F., Carson, D.A., and Chen, P.P. (1992). Genetic analysis of self-associating immunoglobulin G rheumatoid factors from two rheumatoid synovia implicates an antigen-driven response. J. Exp. Med. 175, 831-842.
22. Olsen, N.J., Cush, J.J., Lipsky, P.E., Sinclair, E.W., Cannon, G., McCune, W.J., Strand, V., and Lorenz, T. (1994). Multicenter trial of an anti-CD5 immunoconjugate in rheumatoid arthritis (RA). Arthritis Rheum. 37, S295.
23. Pincus, T., and Callahan, L.F. (1993). What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 19, 123-151.
24. Plater-Zyberk, C., Maini, R.N., Lam, K., Kennedy, T.D., and Janossy, G. (1985). A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum. 28, 971-976.
25. Rankin, E.C.C., Choy, E.H.S., Kassimos, D., Kingsley, G.H., Sopwith, S.M., Isenberg, D.A., and Panayi, G.S. (1995). The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334-342.
26. Ronnelid, J., Lysholm, J., Engstrom-Laurent, A., Klareskog, L., and Heyman, B. (1994). Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum. 37, 1023-1029.
27. Sebbag, M., Simon, M., Vincent, C., Masson-Bessiere, C., Girbal, E., Jean-Jacques, D., and Serre, E. (1995). The anti-perinuclear factor and the so-called anti-keratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95, 2672-2679.
28. Stasny, P. (1978). Association of the B cell alloantigen DRW4 with rheumatoid arthritis. N. Engl. J. Med. 298, 869-871.
29. Thorbecke, G.J., Shah, R., Leu, C.H., Kuruvilla, A.P., Hardison, A.M., and Palladino, M.A. (1992). Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89, 7375-7379.
30. Todd, J.A., Acha-Orbea, H., Bell, J.I., Chao, N., Fronek, Z., Jacob, C.O., McDermott, M., Sinha, A.A., Timmerman, L., Steinman, L., and McDevitt, H.O. (1988). A molecular basis for MHC class II associated autoimmunity. Science 240, 1003-1009.
31. van der Lubbe, P.A., Dijkmans, B.A.C., Markusse, H.M., Nassander, U., and Breedveld, F.C. (1995). A randomised, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 38, 1097-1106.
32. Wahl, S.M. (1994). Transforming growth factor β: The Good, the Bad, and the Ugly. J. Exp. Med. 180, 1587-1590.
33. Williams, R.O., Mason, L.J., Feldmann, M., and Maini, R.N. (1994). Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 91, 2762-2766.
34. Woulfe, S.L., Bono, C.P., Zacheis, D.A., Kirschmann, T.A., Baudino, C.S., Karr, R.W., and Schwartz, B.D. (1995). Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401. Arthritis Rheum. 38, 1744-1753.
35. Ziff, M. (1990). Rheumatoid arthritis - Its present and future. J. Rheumatol. 17, 127-133.